Armodafinil
- Generic Name
- Armodafinil
- Brand Names
- Nuvigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 112111-43-0
- Unique Ingredient Identifier
- V63XWA605I
- Background
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patient...
- Indication
用于改善与阻塞性睡眠呼吸暂停（OSA）、发作性睡病或轮班工作障碍（SWD）相关的过度嗜睡的成年患者的清醒度。亦可用于治疗注意缺陷多动障碍、慢性疲劳综合征和重度抑郁症。
- Associated Conditions
- Narcolepsy, Shift-work related sleep disturbance, Somnolence
- Associated Therapies
- -
The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 39
- Registration Number
- NCT02552303
Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 67
- Registration Number
- NCT02478580
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Effect of Armodafinil on Simulated Driving
- Conditions
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 12
- Registration Number
- NCT02468856
- Locations
- 🇺🇸
University of Florida, Clinical and Translational Science Institute, Gainesville, Florida, United States
Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Duke University
- Target Recruit Count
- 81
- Registration Number
- NCT02151253
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Burke Rehabilitation Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT01896128
- Locations
- 🇺🇸
The Burke Rehabilitation Hospital, White Plains, New York, United States
A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01746043
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01624480
- Locations
- 🇺🇸
Teva Investigational Site 23, Raleigh, North Carolina, United States
🇺🇸Teva Investigational Site 1, Atlanta, Georgia, United States
🇺🇸Teva Investigational Site 7, Little Rock, Arkansas, United States
Armodafinil for Patients Starting Hepatitis C Virus Treatment
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Research Foundation for Mental Hygiene, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01470651
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York City, New York, United States
🇺🇸New York-Presbyterian/Weill Cornell Medical Center, New York City, New York, United States
Effect of Nuvigil on Fatigue
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT01460628
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT01330446
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon B. Johnson General Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.